

DAFTAR PUSTAKA

1. Sahay S. Evaluation and classification of pulmonary arterial hypertension. *J Thorac Dis* 2019; 11: S1789–S1799.
2. Simonneau G, Hoeper MM. The revised definition of pulmonary hypertension: Exploring the impact on patient management. *European Heart Journal, Supplement* 2019; 21: K4–K8.
3. Levine DJ. *Pulmonary arterial hypertension: Updates in epidemiology and evaluation of patients*. 2021.
4. Emmons-Bell S, Johnson C, Boon-Dooley A, et al. Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study. *Pulm Circ* 2022; 12: 1–15.
5. Dinarti LK, Anggrahini DW, Lilyasari O, et al. Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines. *Glob Heart* 2021; 16: 1–11.
6. Raihani MU, Yanni M, Asri E, et al. *Gambaran Karakteristik Pasien Hipertensi Arteri Pulmonal di RSUP Dr. M. Djamil Padang Tahun 2017-2021*. Universitas Andalas, 2022.
7. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. *Eur Respir J* 2019; 53.
8. Suciadi LP, Saboe A, Rahimah AF, et al. Hipertensi Arteri Pulmonal. In: *Pedoman Diagnosis dan Tatalaksana Hipertensi Pulmonal*. Jaka: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, 2021, pp. 20–45.
9. Eichstaedt CA, Benjamin N, Xanthouli P, et al. The role of rehabilitation in patients with pulmonary arterial hypertension. *Curr Opin Pulm Med* 2019; 25: 398–404.
10. Niebauer J. *Cardiac Rehabilitation Manual*. Springer International Publishing, Cham, 2017.
11. Noonan V, Dean E. Submaximal Exercise Testing: Clinical Application and Interpretation. *Phys Ther* 2000; 8: 782–807.
12. Bourgeois A, Omura J, Habbout K, et al. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets. *Int J Biochem Cell Biol* 2018; 104: 9–13.
13. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: Pathogenesis and clinical management. *BMJ* 2018; 360.
14. Humbert M, Hoeper MM, Berger RMF, et al. 2022 ESC / ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung. *Eur Heart J* 2022; 1–114.

- 
15. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hypertension. *Eur Hear Journal, Suppl* 2019; 21: K9–K20.
 16. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2015; 46: 903–975.
 17. Laveneziana P, Garcia G, Jourea B, et al. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. *Eur Respir J* 2013; 41: 578–587.
 18. Malenfant S, Potus F, Mainguy V, et al. Impaired skeletal muscle oxygenation and exercise tolerance in pulmonary hypertension. *Med Sci Sports Exerc* 2015; 47: 2273–2282.
 19. Malenfant S, Brassard P, Paquette M, et al. Compromised cerebrovascular regulation and cerebral oxygenation in pulmonary arterial hypertension. *J Am Heart Assoc* 2017; 6.
 20. Müller-Mottet S, Hildenbrand FF, Keusch S, et al. Effects of Exercise and Vasodilators on Cerebral Tissue Oxygenation in Pulmonary Hypertension. *Lung* 2015; 193: 113–120.
 21. Ozemek C, Berry MJ, Arena R. A Review of Exercise Interventions in Pulmonary Arterial Hypertension and Recommendations for Rehabilitation Programming. *J Cardiopulm Rehabil Prev* 2019; 39: 138–145.
 22. Benjamin N, Marra AM, Eichstaedt C, et al. Exercise Training and Rehabilitation in Pulmonary Hypertension. *Heart Fail Clin* 2018; 14: 425–430.
 23. Grünig E, Eichstaedt C, Barberà JA, et al. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. *Eur Respir J* 2019; 53.
 24. Grünig E, MacKenzie A, Peacock AJ, et al. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: Results from a large European multicentre randomized controlled trial. *Eur Heart J* 2021; 00: 1–12.
 25. Bussotti M, Gremigni P, Pedretti RFE, et al. Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study. *Cardiovasc Hematol Disord Targets* 2016; 17
 26. Radi BR, Suryaatmaja B, Kuncoro AS, et al. Simple and Short-term Inspiration Training Accelerates Recovery from Residual Pulmonary Hypertension after Mitral Valve Surgery: A randomized control trial. *Indones J Cardiol* 2021; 15–23.
 27. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. *Circulation* 2006; 114: 1482–1489.

28. PERKI. *Panduan Rehabilitasi Kardiovaskular*. 1st ed. Jakarta: PERHIMPUNAN DOKTER SPESIALIS KARDIOVASKULAR INDONESIA, 2019.
29. Demir R, Kucukoglu MS. Six-minute walk test in pulmonary arterial hypertension. *Anatol J Cardiol* 2015; 15: 249–254.
30. Casanova C, Celli BR, Barria P, et al. The 6-min walk distance in healthy subjects: Reference standards from seven countries. *Eur Respir J* 2011; 37: 150–156.
31. Farber HW, Miller DP, McGoon MD, et al. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. *J Heart Lung Transplant* 2015; 34: 362–368.
32. American Thoracic Society. ATS Statement : Guidelines for the Six-Minute Walk Test. *Am J Respir Crit Care Med* 2002; 166: 111–117.
33. Miot HA. Sample size in clinical and experimental. *J Vasc Bras* 2011; 10: 275–278.
34. Vari R, Scazzocchio B, D'Amore A, et al. Gender-related differences in lifestyle may affect health status. *Ann Ist Super Sanità* 2016; 52: 158–166.
35. Austin ED, Lahm T, West J, et al. Sex hormones and pulmonary hypertension. *Pulm Circ*. 2013; 3(2): 294–314.
36. Conde R, Londoño A, Pacheco M, et al. Underweight/overweight syndrome in patients with pulmonary hypertension in Colombia: a prevalence study. *European Respiratory Journal* 2022; 60 (suppl 66) 869.
37. Dinarti, L.K., Hartopo, A.B., Kusuma, A.D. et al. The COngenital HeART Disease in adult and Pulmonary Hypertension (COHARD-PH) registry: a descriptive study from single-center hospital registry of adult congenital heart disease and pulmonary hypertension in Indonesia. *BMC Cardiovasc Disord* 2020; 163
38. Cossío-Aranda J, Zamora KDV, Nanda NC, et al. Echocardiographic correlates of severe pulmonary hypertension in adult patients with ostium secundum atrial septal defect. *Echocardiography* 2016; 33: 1891–1896.
39. Post, M.C. Association between pulmonary hypertension and an atrial septal defect. *Neth Heart J* 2013; 21: 331–332.
40. Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: The SUPER-2 study. *Chest* 2011; 140: 1274–1283.
41. Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. *Cochrane Database Syst Rev*. 2019
42. Mandras SA, Mehta HS, Vaidya A. Pulmonary Hypertension: A Brief Guide for Clinicians. *Mayo Clinic Proceedings* 2020; 95: 1978–1988.
43. Bersohn MM, Turner MP, Traiger GL, et al. Systemic BP and heart rate as prognostic indicators in pulmonary arterial hypertension. *Chest* 2013; 144: 959–965.

44. Rich JD and Rich S. Clinical Diagnosis of Pulmonary Hypertension. *Circulation* 2014;130:1820–1830.
45. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, et al. Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial. *Eur Heart J.* 2016;37(1):35-44
46. Grünig, E., Maier, F., Ehlken, N. et al. Exercise training in pulmonary arterial hypertension associated with connective tissue diseases. *Arthritis Res Ther* 2012;14
47. Chia KSW, Shiner CT, Brown K, et al. The exercise in pulmonary arterial hypertension (ExPAH) study: A randomized controlled pilot of exercise training and multidisciplinary rehabilitation in pulmonary arterial hypertension. *Pulm Circ* 2022; 12.
48. Albanaqi AL, Rahimi GRM, Smart NA. Exercise Training for Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Biol Res Nurs* 2021; 23: 442–454.
49. Zhang X, Xu D. Effects of exercise rehabilitation training on patients with pulmonary hypertension. *Pulm Circ* 2020; 10.
50. Martínez-Quintana E, Miranda-Calderín G, Ugarte-Lopetegui A, et al. Rehabilitation program in adult congenital heart disease patients with pulmonary hypertension. *Congenit Heart Dis* 2010; 5: 44–50.
51. Seo YG, Oh S, Park WH, et al. Optimal aerobic exercise intensity and its influence on the effectiveness of exercise therapy in patients with pulmonary arterial hypertension: A systematic review. *J Thorac Dis* 2021; 13: 4530–4540.
52. Mainguy V, Maltais F, Saey D, et al. Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. *J Cardiopulm Rehabil Prev* 2010; 30: 319–323.
53. Luo Z, Qian H, Zhang X, et al. Effectiveness and safety of inspiratory muscle training in patients with pulmonary hypertension: A systematic review and meta-analysis. *Front Cardiovasc Med* 2022; 9.
54. Laddha AP, Kulkarni YA. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders. *Respir Med* 2019; 156: 33–46.
55. Schäfer K, Tello K, Pak O, et al. Decreased plasma levels of the brain-derived neurotrophic factor correlate with right heart congestion in pulmonary arterial hypertension. *ERJ Open Res* 2023;9.